S&P/ASX All Ords (ASX: XAO) shares are up 1.04% during a great day for the Aussie share market.
The All Ords enjoyed strong momentum in January, with the index lifting an impressive 4.38%.
Here are five ASX All Ords shares that brokers upgraded to a strong buy rating last month.
5 ASX All Ords shares elevated to 'strong buy' status
The consensus rating on these ASX All Ords shares from market analysts on the CommSec trading platform is a strong buy.
CSL Ltd (ASX: CSL)
Analysts upgraded their consensus rating on CSL shares to a strong buy on 29 January.
The CSL share price is $272.30, up 0.72% at the time of writing.
The market's largest healthcare share by market capitalisation has fallen 9.8% over the past 12 months.
Chalice Mining Limited (ASX: CHN)
Analysts upgraded their consensus rating on Chalice Mining to a strong buy on 23 January.
The Chalice Mining share price is currently $1.23, down 0.24%.
The ASX All Ords mining share is up 40% over the past 12 months.
Abacus Storage King (ASX: ASK)
Analysts upgraded their consensus rating on Abacus Storage shares on 16 January.
The ASX real estate investment trust (REIT) is trading at $1.15 on Thursday, up 1.32%.
Analysts say ASX REITs will benefit from the global trend of falling interest rates.
Top broker JPMorgan has an overweight rating on Abacus Storage King shares.
The ASX All Ords REIT share has risen by only 0.88% over the past 12 months.
Boss Energy Ltd (ASX: BOE)
Brokers upgraded ASX All Ords uranium share Boss Energy to a strong buy on 10 January.
This was despite plenty of short plays on the stock last month.
The upgraded rating came ahead of the company's quarterly update on 29 January, which led to a 16.5% spike in the Boss Energy share price over the last three trading days of the month.
Boss Energy shares rose by 36.2% in January — the strongest result of the ASX 200.
The Boss Energy share price is $3.38, down 0.29% today and down 44% over the past year.
Mesoblast Limited (ASX: MSB)
The No. 1 ASX All Ords share for price growth in 2024 received an upgraded consensus rating on 2 January.
This followed big news from Mesoblast in December.
The company announced that its flagship drug, Ryoncil, or remestemcel-L, had finally gained approval from the United States Food and Drug Administration after many years of trials.
Ryoncil is the first approved treatment for steroid-refractory acute graft versus host disease (SR-aGvHD) in children aged two months and older.
It is also the first mesenchymal stromal cell (MSC) therapy ever approved in the US.
The ASX All Ords biotech share is down 2.81% at $2.94 on Thursday.
Mesoblast shares have skyrocketed by 1,029% over the past 12 months.
